Chicago Capital LLC Has $55.92 Million Stock Holdings in Insulet Corporation $PODD

Key Points

• Chicago Capital LLC increased its stake in Insulet Corporation by 3.9% during the second quarter, now holding approximately $55.92 million in shares.
• Insulet reported a strong quarterly performance, with earnings per share of $1.17, exceeding estimates, and a revenue increase of 32.9% year-over-year.
• Several institutional investors, including Vanguard Group and American Century Companies, have increased their stakes in Insulet recently, indicating strong institutional interest in the stock.

Chicago Capital LLC raised its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 3.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 177,996 shares of the medical instruments supplier's stock after purchasing an additional 6,702 shares during the quarter. Insulet accounts for 1.4% of Chicago Capital LLC's portfolio, making the stock its 28th largest holding. Chicago Capital LLC owned approximately 0.25% of Insulet worth $55,923,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PODD. Vanguard Group Inc. grew its stake in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after buying an additional 178,976 shares during the last quarter. American Century Companies Inc. grew its stake in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after buying an additional 297,734 shares during the last quarter. Groupama Asset Managment grew its stake in Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after buying an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Insulet by 4.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after buying an additional 27,408 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Insulet by 23.4% during the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock valued at $166,198,000 after purchasing an additional 120,197 shares during the last quarter.

Insulet Trading Down 2.3%

PODD opened at $310.62 on Tuesday. The firm's fifty day moving average is $319.60 and its two-hundred day moving average is $297.72. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a twelve month low of $225.37 and a twelve month high of $353.50. The firm has a market cap of $21.86 billion, a PE ratio of 94.41, a price-to-earnings-growth ratio of 2.64 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The firm's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on PODD. Truist Financial began coverage on shares of Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 price target on the stock. Barclays raised their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Canaccord Genuity Group raised their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a "buy" rating in a research note on Monday. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $345.76.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.